Hong Kong-based Cornerstone Robotics has raised around $200m in its funding round, mainly to expedite commercialisation plans and propel technology advancements.
The oversubscribed financing round saw participation from an international investor, several global institutional and sovereign wealth funds, as well as current backers.
According to the company, this diverse investor group is expected to strengthen its international reach and support its aim of making surgical robotic technologies more widely available around the world.
Established in 2019, Cornerstone develops surgical robotics and related technologies through internal research and vertical integration.
Its main offering, the Sentire Endoscopic Surgical System, has secured China’s National Medical Products Administration approval and is currently being used clinically in hospitals across mainland China, Europe, and Hong Kong.
The company also partners with academic and medical institutions internationally to support technology adoption, clinical training, and academic exchange.
UBS Group acted as the company’s financial adviser for this transaction. Legal counsel was provided by Global Law Office for transactional matters and JunHe for intellectual property.
Cornerstone Robotics founder and CEO professor Samuel Au said: “The year 2025 marks an important milestone in the development journey of Cornerstone Robotics. We extend our heartfelt gratitude to our new and existing shareholders for their trust and support.
“This represents not only recognition of the successful clinical application of our innovations, but also strong confidence in Cornerstone Robotics’ long-term growth. Moving forward, we will remain committed to innovation-driven development and deepen our global presence, bringing safe, high-quality, and accessible surgical robotic solutions to patients and healthcare providers around the world.”
In January, Cornerstone secured more than $70m in a Series C financing round, aimed towards expediting commercialisation efforts, developing new products, performing clinical studies, seeking regulatory clearances, and the global expansion of robotic surgical solutions.
